Why is xhance nasal spray so expensive

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Xhance nasal spray is expensive primarily due to its patented drug delivery system and specialized formulation. The FlutiCare delivery device, which uses exhalation to deposit medication deep in nasal passages, received FDA approval in 2017. Without insurance, Xhance can cost over $500 per month, though prices vary by pharmacy and coverage. The manufacturer, Optinose, holds patents protecting this technology until at least 2034.

Key Facts

Xhance received FDA approval in September 2017 for treating nasal polyps
The FlutiCare delivery device uses exhalation to deposit medication deep in nasal passages
Without insurance, Xhance typically costs $500-$700 per month
Optinose holds patents protecting Xhance's delivery technology until 2034
Xhance contains fluticasone propionate, a corticosteroid also used in other nasal sprays

Overview

Xhance (fluticasone propionate) is a prescription nasal spray developed by Optinose specifically for treating nasal polyps in adults. Unlike traditional nasal sprays that rely on manual pumping, Xhance utilizes a patented exhalation delivery system called FlutiCare that was FDA-approved in September 2017. This innovative approach represents a significant advancement in nasal drug delivery, allowing medication to reach deeper nasal passages where polyps typically form. The technology originated from research at the University of Pennsylvania and was commercialized by Optinose, a pharmaceutical company founded in 2000. Clinical trials demonstrated Xhance's effectiveness in reducing nasal polyp size and improving symptoms, leading to its approval as the first drug specifically indicated for nasal polyps with this delivery method. The specialized formulation contains 93 mcg of fluticasone propionate per spray, delivered through a unique bidirectional mechanism.

How It Works

Xhance's FlutiCare delivery system operates through a three-step process that distinguishes it from conventional nasal sprays. First, the user places the device in their mouth and seals their lips around the mouthpiece. Second, they blow steadily into the device while simultaneously activating the spray mechanism with their thumb. This exhalation creates positive pressure that closes the soft palate, preventing medication from entering the throat. Third, the medication is propelled through the nasal adapter and into the nasal cavity, where the exhalation helps distribute it to deeper nasal regions, including the sinuses where polyps develop. The system delivers medication in a fine mist that coats more surface area than traditional sprays. This method increases drug deposition in posterior nasal regions by approximately 300% compared to conventional sprays, according to Optinose studies. The device requires proper technique for optimal delivery, and patients typically receive training from healthcare providers.

Why It Matters

Xhance addresses a significant medical need for chronic rhinosinusitis with nasal polyps, a condition affecting approximately 4% of the U.S. population. Traditional nasal sprays often fail to reach affected areas effectively, leading to inadequate treatment and frequent need for surgical interventions. By delivering medication directly to polyp formation sites, Xhance can reduce polyp size and symptoms, potentially decreasing the need for repeated surgeries that cost thousands of dollars each. The technology represents a paradigm shift in nasal drug delivery that could influence future respiratory medications. However, the high cost creates access barriers, with many patients requiring prior authorization from insurance companies. The expense reflects both the specialized delivery system and the clinical development costs, but it also raises questions about medication affordability in specialty pharmaceuticals.